Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications - Wikidata - wikimedia - TriplyDB

Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications

Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications

http://www.wikidata.org/entity/Q34381790

about

Identification of druggable cancer driver genes amplified across TCGA datasets Nutraceuticals in Parkinson's Disease Past strategies and future directions for identifying AMP-activated protein kinase (AMPK) modulators Dissecting the Dual Role of AMPK in Cancer: From Experimental to Human Studies Reduced expression of AMPK-β1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer Dysregulation of RNA polymerase I transcription during disease.An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma Glucose-based regulation of miR-451/AMPK signaling depends on the OCT1 transcription factor.Rare coding variants and X-linked loci associated with age at menarche.Prognostic significance of AMPK in human malignancies: A meta-analysis.When Anti-Aging Studies Meet Cancer Chemoprevention: Can Anti-Aging Agent Kill Two Birds with One Blow?Targeting AMPK signaling in combating ovarian cancers: opportunities and challenges.mir-101-3p is a key regulator of tumor metabolism in triple negative breast cancer targeting AMPK.CD74: a new prognostic factor for patients with malignant pleural mesothelioma.AMPK: a contextual oncogene or tumor suppressor?Activators of AMPK: not just for type II diabetes.Screening methods for AMP-activated protein kinase modulators: a patent review.AMPK β1 reduces tumor progression and improves survival in p53 null mice.Functional characterization of AMP-activated protein kinase signaling in tumorigenesis.PBX3 is targeted by multiple miRNAs and is essential for liver tumour-initiating cells.AMPK and Cancer.Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.Consensus reference gene(s) for gene expression studies in human cancers: end of the tunnel visible?

P2860

Q21090621-B7E21115-7247-4BFC-AC35-AEC10B725F96 Q26752769-E9722382-B6F3-4212-89F0-3776B0CDC3EC Q26864679-DF8AF730-D64F-4467-BC19-E9342AE4593A Q28081491-F0642D7A-B984-47B6-ABB4-90ADB1FDB3EC Q33590428-E76A865B-FD98-4948-B14F-05F2B908935D Q34645436-AD553A65-23A4-4360-A03A-330B25062C99 Q34926232-AB6973E5-1388-4825-89E3-D4F7D5F00D87 Q35607018-D6DED96F-30D0-47B8-96AB-7D7A9497C8DA Q35961979-7434629F-F4F3-4556-BCED-11312BD5CD7D Q36157437-203EB000-3F36-4050-8FF1-58188D057031 Q36442945-A2BE5110-876A-49A9-82FB-0C347E50C39A Q36949580-D4968C4C-3019-481F-98D6-F911907252F9 Q37376505-BC46F45B-D9D5-4F23-A88C-87C886C024C4 Q37711647-4FC2081A-DE70-4D96-8DDC-44071CB50E77 Q38104227-1250A3C0-05B7-42CA-9ADA-05F83F213A71 Q38243893-6C9B29BA-66EF-4943-86D3-5E66E0266733 Q38298547-B25D93E0-F543-426B-B5E7-884609C4DD04 Q38764024-19088C2D-68F4-4EB5-BA91-01263D3D640D Q38807302-3FDCB48E-9F42-42DB-8F86-76F125DC29B9 Q38831430-7BBB26A5-BEF2-4F9C-92CE-4727A384091E Q38998413-B852F95F-6C92-407D-B887-7A1C8F1E5607 Q50915266-1CD4F407-7371-4760-9FEB-E8DCE43DF9B1 Q53527300-017DC87C-522C-4675-BA6C-5E87C4216AE3

P2860

Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications

http://www.wikidata.org/entity/Q34381790

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Over-expressions of AMPK subun ...... nificant clinical implications

@ast

Over-expressions of AMPK subun ...... nificant clinical implications

@en

Over-expressions of AMPK subun ...... nificant clinical implications

@nl

type

label

Over-expressions of AMPK subun ...... nificant clinical implications

@ast

Over-expressions of AMPK subun ...... nificant clinical implications

@en

Over-expressions of AMPK subun ...... nificant clinical implications

@nl

prefLabel

Over-expressions of AMPK subun ...... nificant clinical implications

@ast

Over-expressions of AMPK subun ...... nificant clinical implications

@en

Over-expressions of AMPK subun ...... nificant clinical implications

@nl

P1433

Q34381790-A4FA5F0B-9C3E-41A8-8ACA-BBD696114BE8

P1476

Q34381790-6A440D04-4378-42CA-924C-A562CAFAB8C9

P2093

Q34381790-1E5A22F1-669E-4BB7-AFD9-69CD5B260346

Q34381790-3081F31D-7A85-45E6-9018-EB2D4EDFAB38

Q34381790-4209EE4C-0A42-4F87-8A9F-0658FFA75C41

Q34381790-D74291D5-BF00-49FD-8A8D-5EC8C1622225

Q34381790-EFCF11FD-F01E-4724-AC94-51232B43D7BB

P2860

Q34381790-0FDBDA7D-9154-4EC4-BFAA-A64F7D436081

Q34381790-1D66418F-8832-4815-8A6B-2726CF26F62F

Q34381790-2142751C-CE2C-471D-BD2C-D6F6D37A1E65

Q34381790-40E865BF-AE31-4869-A4CF-226ECAEBDBA3

Q34381790-4F192DCE-6A0D-4161-A254-62CCC15658E1

Q34381790-536C9F33-059E-45BE-A0A4-95BC31BBADD3

Q34381790-5DC4888D-C908-4E39-A96B-A368F5D77019

Q34381790-5EEE6030-CB0C-4433-9CE4-E8365316ACE5

Q34381790-5EFFA5B5-8B68-4E87-9ED7-85F87BA5B18A

Q34381790-896C3D66-10FD-471D-AD99-6B42029FD9E1

P2888

Q34381790-1A075BF1-71FD-46DE-B865-7B9B91C49F6D

P304

Q34381790-467A1EB2-1812-4198-9123-9C172360B819

P31

Q34381790-EF859F52-D873-445C-A2AA-DA72008E61AB

P356

Q34381790-11216146-A855-4D95-B9AD-28D993FAA2E7

P407

Q34381790-55D1ACAE-E9AD-4F56-B883-03B7A0B12D10

P478

Q34381790-F21F7AC4-86DB-4FFA-BB52-9A9ABB103ED0

P577

Q34381790-C44B80BB-0AB2-4098-887E-0F74AB4E8B09

P5875

Q34381790-B0714CA0-B060-4CFD-A97C-94937B3F6C6B

P6179

Q34381790-8AF2A321-122E-4AFB-BE5A-4282490005CE

P698

Q34381790-27965CBC-3D64-4737-9F87-23460F98F14B

P932

Q34381790-80404F2A-46B2-4CD4-9159-07510B0FA70C

P356

1471-2407-12-357

P1433

P1476

Over-expressions of AMPK subun ...... nificant clinical implications

@en

P2093

Cuilan Li

http://www.w3.org/2001/XMLSchema#string

David W Chan

http://www.w3.org/2001/XMLSchema#string

Hextan Ys Ngan

http://www.w3.org/2001/XMLSchema#string

Pui M Chiu

http://www.w3.org/2001/XMLSchema#string

Vincent Ws Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Analyzing real-time PCR data by the comparative C(T) method

The LKB1-AMPK pathway: metabolism and growth control in tumour suppression

AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy

Kinase activity-independent suppression of p73alpha by AMP-activated kinase alpha (AMPKalpha).

AMPK/LKB1 signaling in epithelial cell polarity and cell division.

Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner

AMPK in Health and Disease.

Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer.

AMPK-beta1 subunit is a p53-independent stress responsive protein that inhibits tumor cell growth upon forced expression.

Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins.

P2888

1471-2407-12-357

P304

357

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-12-357

http://www.w3.org/2001/XMLSchema#string

P407

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230684517

http://www.w3.org/2001/XMLSchema#string

P6179

1004784114

http://www.w3.org/2001/XMLSchema#string

P698

22897928

http://www.w3.org/2001/XMLSchema#string

P932

3518102

http://www.w3.org/2001/XMLSchema#string